Effects of Cannabidiol (CBD) on a Fixed Dose of Delta-9-tetrahydrocannabinol (THC)

This study will evaluate the subjective and behavioral effects of cannabis products containing delta-9-tetrahydrocannabinol and cannabidiol

Inclusion Criteria: * at least 21 years old; * be in good general health based on screening procedures (e.g., physical exam, EKG, blood testing, psychiatric evaluation); * have vital signs in normal range; * have not donated blood in past 30 days; * not be pregnant (assessed via blood serum at screening and urinalysis before each study session) or breast feeding (women only); * have a body mass index (BMI) in the range of 18 to 36 kg/m\^2; * report using cannabis in the last 3 years, but not in the past month; * negative urine test for illicit drug use (including THC) and negative breath alcohol test (0% breath alcohol concentration) at screening and before study sessions. Exclusion Criteria: * psychoactive drug use (aside from nicotine, alcohol, or caffeine) in past month; * current use of over the counter (OTC) drugs, supplements/vitamins, or prescription medications that, in the opinion of the investigator or medical staff, will impact the participant's safety or pharmacokinetics (PK) of the study drugs; * history of or current evidence of significant medical condition; * evidence of current psychiatric condition (based on MINI); * been in treatment previously for cannabis use disorder; * liver function tests more than 2x normal range; * enrollment in another clinical trial or receiving of any drug as part of research within past 30 days; * epilepsy or a history of seizures